Guggenheim Maintains Buy on Zevra Therapeutics, Lowers Price Target to $24
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice Target
Guggenheim analyst Eddie Hickman maintains Zevra Therapeutics (NASDAQ:ZVRA) with a Buy and lowers the price target from $29 to $24.
Guggenheim analyst Eddie Hickman maintains Zevra Therapeutics (NASDAQ:ZVRA) with a Buy and lowers the price target from $29 to $24.